Cambridge Investment Research Advisors
AMPH icon

Cambridge Investment Research Advisors’s Amphastar Pharmaceuticals AMPH Stock Holding History

Cambridge Investment Research Advisors’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,790
Closed -$400K – 3616
2025
Q1 		$400K Buy
13,790
+1,694
+14% +$54.1K ﹤0.01% 2640
2024
Q4 		$449K Buy
12,096
+181
+2% +$8.28K ﹤0.01% 2514
2024
Q3 		$578K Buy
11,915
+45
+0.4% +$1.98K ﹤0.01% 2292
2024
Q2 		$475K Buy
+11,870
New +$492K ﹤0.01% 2339

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Cambridge Investment Research Advisors's AMPH Position: Q2 2025 in Review

Cambridge Investment Research Advisors sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2025, closing a stake of 13,790 shares — an estimated $400K sold.

Cambridge Investment Research Advisors first reported a position in AMPH in Q2 2024 and held it in 4 quarters. The position peaked at $578K in Q3 2024. 245 funds tracked by Wall St. Rank hold AMPH as of Q2 2025.

  • Cambridge Investment Research Advisors reported no remaining Amphastar Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 13,790 Amphastar Pharmaceuticals shares in Q2 2025, an estimated $400K.
  • Cambridge Investment Research Advisors first reported a position in Amphastar Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Cambridge Investment Research Advisors's Amphastar Pharmaceuticals position peaked at $578K in Q3 2024.
  • 245 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2025.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2025, filed 31 Jul 2025.